Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®)
DOI:
https://doi.org/10.12775/QS.2024.25.56711Keywords
Leqembi, Lecanemab, Alzheimer's disease, BAN2401Abstract
Alzheimer's disease represents one of the most significant challenges in the field of neurology, affecting millions of individuals worldwide. In pursuing efficacious treatments, lecanemab has emerged as a promising therapeutic option. This pioneering monoclonal antibody targets and reduces amyloid-beta plaques in the brain, a defining feature of Alzheimer's disease. By addressing one of the fundamental causes of the disease, lecanemab represents a novel approach to slowing its progression.
On 14th November 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting marketing authorisation for Leqembi® (whose active substance is lecanemab). This recommendation is specifically directed towards patients with early-onset Alzheimer's disease who are non-carriers or heterozygotes for the apolipoprotein E ε4 (ApoE ε4) allele, thereby underscoring the drug's efficacy tailored to specific genetic profiles (Committee for Medicinal Products for Human Use, 2024).
The CHMP's approval is a testament to the extensive research and clinical trials that have demonstrated the efficacy and safety of Leqembi® (Lecanemab). This narrative review aims to provide a comprehensive examination of these aspects and offer a detailed understanding of the potential impact of this treatment on the management of early Alzheimer's disease.
References
Abdelazim K, Allam AA, Afifi B, Abdulazeem H, Elbehiry AI. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Neurol Sci. 2024;45(8):3583-3597. doi:10.1007/s10072-024-07477-w
Chowdhury S, Chowdhury NS. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review. Int J Immunopathol Pharmacol. 2023;37:3946320231209839. doi:10.1177/03946320231209839
Cohen S, van Dyck CH, Gee M, et al. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2023;10(4):771-777. doi:10.14283/jpad.2023.123
Costa T, Premi E, Liloia D, Cauda F, Manuello J. Unleashing the Power of Bayesian Re-Analysis: Enhancing Insights into Lecanemab (Clarity AD) Phase III Trial Through Informed t-Test. J Alzheimers Dis. 2023;95(3):1059-1065. doi:10.3233/JAD-230589
Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. doi:10.14283/jpad.2023.30
Dhadda S, Kanekiyo M, Li D, et al. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease. Alzheimers Res Ther. 2022;14(1):182. Published 2022 Dec 9. doi:10.1186/s13195-022-01129-x
Granzotto A, Sensi SL. Once upon a time, the Amyloid Cascade Hypothesis. Ageing Res Rev. 2024;93:102161. doi:10.1016/j.arr.2023.102161
Honig LS, Barakos J, Dhadda S, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Alzheimers Dement (N Y). 2023;9(1):e12377. Published 2023 Mar 20. doi:10.1002/trc2.12377
Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease [published correction appears in Alzheimers Res Ther. 2024 Jul 10;16(1):159. doi: 10.1186/s13195-024-01507-7]. Alzheimers Res Ther. 2024;16(1):105. Published 2024 May 10. doi:10.1186/s13195-024-01441-8
Johannesson M, Söderberg L, Zachrisson O, et al. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains. Mol Cell Neurosci. 2024;130:103949. doi:10.1016/j.mcn.2024.103949
Knopman DS, Hershey L. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?. Neurology. 2023;101(14):610-620. doi:10.1212/WNL.0000000000207438
Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease. Adv Clin Exp Med. 2023;32(9):943-947. doi:10.17219/acem/171379
McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191. Published 2022 Dec 21. doi:10.1186/s13195-022-01124-2
Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci. 2023;15:1169499. Published 2023 May 5. doi:10.3389/fnagi.2023.1169499
Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023;19(4):1227-1233. doi:10.1002/alz.12748
Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics. 2023;20(1):195-206. doi:10.1007/s13311-022-01308-6
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody [published correction appears in Alzheimers Res Ther. 2022 May 21;14(1):70. doi: 10.1186/s13195-022-00995-9]. Alzheimers Res Ther. 2021;13(1):80. Published 2021 Apr 17. doi:10.1186/s13195-021-00813-8
Swanson CJ, Zhang Y, Dhadda S, et al. Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2022;14(1):70. Published 2022 May 21. doi:10.1186/s13195-022-00995-9
Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling. Neurol Ther. 2022;11(2):863-880. doi:10.1007/s40120-022-00350-y
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol (Paris). 2022;178(10):1011-1030. doi:10.1016/j.neurol.2022.06.012
Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2023;32(2):89-94. doi:10.1080/13543784.2023.2178414
Wu W, Ji Y, Wang Z, et al. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023;28(1):544. Published 2023 Nov 28. doi:10.1186/s40001-023-01512-w
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Adrianna Muciek, Martyna Mocarska, Anna Orłowska, Katarzyna Strakowska, Laura Opalska, Anna Maryńczak, Jan Mencel, Nicole Nitschke
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 409
Number of citations: 0
